Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck, Medicines Patent Pool Sign Licensing Agreement To Distribute COVID-19 Pill in Low-, Middle-Income Countries

10/27/2021 | 10:00am EST


ę MT Newswires 2021
All news about MERCK & CO., INC.
05:52pMerck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigation..
BU
05:35pMerck & Co. COVID-19 Pill Receives Recommendation From FDA Advisory Panel Despite Safet..
MT
04:37pMerck & Company Lifts Q1 2022 Dividend to $0.69/Share From $0.65/Share, Payable Jan. 7 ..
MT
02:49pMerck Announces First-Quarter 2022 Dividend
BU
02:30pPharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11:00aMerck & Co. Exec Says COVID-19 Drug Likely To Be Effective Against Variants
MT
09:57aMERCK THINKS COVID ANTIVIRAL HAS SIM : Reuters
MT
09:17aWALL STREET STOCK EXCHANGE : Questions about Omicron and vaccine efficiency rattle markets
07:41aMerck & Company's Keytruda Plus Chemotherapy Combination Approved in Japan for Initial ..
MT
07:02aMerck Says Supplemental New Drug Application for Lynparza Accepted, Granted Priority Re..
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 572 M - -
Net income 2021 13 662 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 15,4x
Yield 2021 3,47%
Capitalization 189 B 189 B -
EV / Sales 2021 4,32x
EV / Sales 2022 3,62x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 74,91 $
Average target price 95,25 $
Spread / Average Target 27,2%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-8.45%189 168
JOHNSON & JOHNSON1.16%420 557
ROCHE HOLDING AG15.70%334 662
PFIZER, INC.42.35%294 114
NOVO NORDISK A/S67.75%247 392
ELI LILLY AND COMPANY50.93%231 027